Srinivas Mangala, Melero Ignacio, Kaempgen Eckhart, Figdor Carl G, de Vries I Jolanda M
Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Department of Tumor Immunology, Nijmegen, The Netherlands.
Contrast Media Mol Imaging. 2013 Nov-Dec;8(6):432-8. doi: 10.1002/cmmi.1561.
In vivo imaging plays a key role in cell tracking, particularly for the optimization of cellular therapeutics. A recent trend is to use more than one imaging modality (multimodality imaging) for this purpose. There are several advantages to multimodal cell tracking, particularly the corroboration of data obtained using a new imaging agent or technique with an established one, and the ability to glean complementary information from a single experiment. In this review, we examine the different types of labels and imaging strategies used in the literature for multimodal cell tracking, and discuss the pros and cons of these approaches, with a focus on MRI. Despite many efforts and novel technologies, we still have to face situations where current imaging methods are simply not sensitive enough and new labeling strategies are hampered by the lack of approved reagents. Finally, we examine new in vitro and preclinical developments, which have the potential to tackle unresolved challenges in in vivo multimodal imaging.
体内成像在细胞追踪中起着关键作用，特别是在细胞治疗的优化方面。最近的一个趋势是为此目的使用不止一种成像方式（多模态成像）。多模态细胞追踪有几个优点，特别是将使用新的成像剂或技术获得的数据与已确立的成像剂或技术获得的数据进行确证，以及能够从单个实验中收集互补信息。在这篇综述中，我们研究了文献中用于多模态细胞追踪的不同类型的标记物和成像策略，并讨论了这些方法的优缺点，重点是磁共振成像（MRI）。尽管付出了许多努力并出现了新技术，但我们仍然不得不面对当前成像方法不够灵敏以及新的标记策略因缺乏获批试剂而受阻的情况。最后，我们研究了新的体外和临床前进展，这些进展有可能解决体内多模态成像中尚未解决的挑战。
